ABUS Arbutus Biopharma Corp.

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 – 14, 2021.

Arbutus Fireside Chat Presenters:

William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.

A webcast of the virtual fireside chat will be available starting at 6:00 am (EST) on January 11, 2021, and can be accessed through the Investors section of Arbutus' website at or directly at . An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit .

Contact Information

Investors and Media

William H. Collier

President and CEO

Phone: 267-469-0914

Email:

Pam Murphy

Investor Relations Consultant

Phone: 267-469-0914

Email:



EN
04/01/2021

Underlying

ABUSArbutus Biopharma Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arbutus Biopharma Corp.

 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus to Report First Quarter 2024 Financial Results and Provide Cor...

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows: •Q1 2024 Press Release:Thursda...

April 18, 2024 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing P...

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plain...

April 4, 2024 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus to Participate in Two Upcoming Investor Conferences WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL: Barclays 26th Annual Global Healthcare Conference: Formal Presentation on Ma...

March 8, 2024 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and...

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial with imdusiran in first half of 2024 Claim Construction for Moderna LNP litigation occurred on February 8, 2024; trial date set for April 21, 2025 Strong financial position with cash and investments of $132M; cash runway into Q1 2026  Conference Call and Webcast Today at 8:45 am ET WA...

February 29, 2024 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results a...

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows...

February 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch